At one level, the UK medicines supply chain – from manufacturer to wholesaler to community pharmacies – is a relatively simple one. The originator of...
It was good to see the letter sent to C+D by the pharmacy minister, Seema Kennedy, last week. We all broadly welcome the commitment to an expanded...
As one of the UK’s largest generics manufacturers, the suspension of Bristol Laboratories’ licence in 2017 prompted severe shortages, which the...
The Pharmaceutical Services Negotiating Committee (PSNC) director of pharmacy funding Mike Dent told C+D that, “while there have always been...
The Department of Health and Social Care (DH) was granted powers in July 2017 to impose changes to medicine prices when it thinks “inappropriate...
The focus on the UK’s impending exit from the European Union has generated significant and widespread planning and preparation, particularly around...
The Medicines and Healthcare products Regulatory Agency (MHRA) first issued a partial suspension of the manufacturer’s licence in August 2017, after...
The court dismissed Pfizer’s attempt to prevent generic pregabalin from being used to treat certain types of pain, such as neuropathic pain,...
The latest instalment in the sector’s long-running struggles with generic pricing started in September 2017, when the Pharmaceutical Services...
Pre-tax profit for the independent H Shackleton chain in the 12 months to October 2017 fell from £496,000 to £422,000, with half the loss due to the...
Download the C+D app today for free on your iOS or Android phone or tablet. Access the latest and most popular news.
SIGN UP FOR OUR NEWSLETTERS
- C+D Daily Bulletin
- • C+D CPD Bulletin
- • C+D Saturday Review
- • C+D Careers Bulletin
- • C+D Briefing Newsletter